Skip to main content
Full access
LETTER
Published Online: 1 January 2010

Aripiprazole, Hypertension, and Confusion

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Aripiprazole is a second-generation antipsychotic approved for schizophrenia and for the treatment of mania and mixed episodes associated with bipolar disorder. Aripiprazole has also been approved for the treatment of major depressive disorder in adults as an add-on therapy. Aripiprazole exhibits a high affinity for dopamine D2-D3 and serotonin 5-HT1A and 5-HT2A receptors and a moderate affinity for 5-HT2c, alpha1-adrenergic, histamine H1 receptors, and serotonin reuptake pump. It behaves as a partial agonist for D2 and 5-HT1A receptors and as an antagonist for 5-HT2A receptors. 1 In 2005, Borras et al. 2 reported a case of hypertensive crisis associated with the intake of aripiprazole. This phenomenon is quite infrequent and probably related to some individual factors. Here, we describe the case of an elderly depressed woman who developed delirium and a hypertension crisis after the intake of aripiprazole.

Case Report

Mrs. H. is an 80-year-old woman with a 15-year history of major depressive disorder without psychotic features. Previous antidepressant treatments included tricyclics, serotonin reuptake inhibitors, and serotonin-noradrenalin reuptake inhibitors. She also received augmentation strategies such as lithium, olanzapine, and dopaminergic agonists. Tolerance associated with all these therapeutics was always excellent. Unfortunately, she never achieved remission state. Ten years earlier, she underwent a coronary artery bypass graft surgery without any complications. She was treated for many years with low doses of aspirin, pravastatin, and bisoprolol for a moderate hypertension, and she was considered by cardiologists to be very well stabilized. She was treated with venlafaxine, 150 mg, without problems of hypertension related to the medication, and we decided to add aripiprazole, 5 mg, to potentiate the antidepressant effect of venlafaxine. About 48 hours after the first intake of aripiprazole, she became confused with symptoms such as loss of orientation, severe memory disturbances, and agitation. An arterial hypertension of 200/110 mmHg was measured, and the ECG was normal except for tachycardia (110 bpm). We decided to discontinue aripiprazole, and both hypertension and confusion resolved over 48 hours without treatment. The patient had never presented such symptomatology before. Over a period of 1 year, without addition of any new antihypertensive medication, and with venlafaxine treatment maintained during 4 months, the patient never experienced confusion again, and her blood pressure remained below 150/90 mmHg.

Discussion

Our report tends to support the association between aripiprazole and hypertension in a geriatric patient suffering from major depression, confirming the Letter to the Editor published by Borras et al. 2 In addition, the prescription of aripiprazole also induced mental confusion, probably related to acute hypertension. 3 In the present case report, aripiprazole induced hypertension could have been induced by the preexisting cardiovascular risk factors. Another hypothesis could involve association with venlafaxine, an antidepressant known for its ability to increase blood pressure. In conclusion, we can say that particular caution is needed in the geriatric population more prone to polypharmacy and comorbid physical illnesses.

References

1.
McIntyre RS, Soczynska JK, Waldeyohannes HO, et al: Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007; 8:1001–1009
2.
Borras L, Constant EL, Eytan A, et al: Hypertension and aripiprazole. Am J Psychiatry 2005; 162:2392
3.
Ouimet S, Kavanagh BP, Gottfried SB, et al: Delirium is associated with a history of hypertension. Intensive Care Med 2007; 33:66–73

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 123.e33
PubMed: 20160240

History

Published online: 1 January 2010
Published in print: Winter, 2010

Authors

Affiliations

William Pitchot, M.D., Ph.D.
Marc Ansseau, M.D., Ph.D.
Psychiatric Unit, University Hospital of Liège, Sart Tilman, B-4000 Liège, Belgium

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share